Fig. 6: Plasma protein signatures in csDMARDs-treated RA patients with different responses. | Nature Communications

Fig. 6: Plasma protein signatures in csDMARDs-treated RA patients with different responses.

From: A longitudinal cohort study uncovers plasma protein biomarkers predating clinical onset and treatment response of rheumatoid arthritis

Fig. 6

a Volcano plots showing DEPs before and after MTX + LEF treatment, stratified by treatment response (response, n = 12; no response, n = 23) (paired two-sided Student’s t test, p < 0.05). b Volcano plots showing DEPs before and after MTX + HCQ treatment, stratified by treatment response (response, n = 6; no response, n = 13) (paired two-sided Student’s t test, p < 0.05). c Pathway enrichment analysis of DEPs before and after MTX + LEF treatment in response (two-sided Fisher’s exact test). d Pathway enrichment analysis of DEPs before and after MTX + HCQ treatment in response (two-sided Fisher’s exact test). e Heatmap of the relative abundance of DEPs before and after MTX + LEF treatment, separated by response. f Heatmap of the relative abundance of DEPs before and after MTX + HCQ treatment, separated by response. Venn diagrams displaying overlap of treatment- and response-related proteins for MTX + LEF (response, n = 12; no response, n = 23) (g) and MTX + HCQ (response, n = 6; no response, n = 13) (h) therapies, grouped by response, with corresponding dot plots illustrating the differential expression of these proteins among groups (paired two-sided Student’s t test). Significance is indicated as follows: *p < 0.05, **p < 0.01, ns means p ≥ 0.05. Source data are provided as a Source Data file.

Back to article page